Biogen Idec and Elan are equally common in the development of TYSABRI in MS.

Biogen Idec and Elan are equally common in the development of TYSABRI in MS, Crohn’s disease and rheumatoid arthritis. Regulatory authorities in Canada and Australia have designated TYSABRI for Priority Review for the treatment of MS, and the European Medicines Agency is actively reviewing the application. So far, more than 2,800 patients were receiving Tysabri in clinical trials.

Biogen Idec and Elan announced today that they are the initiate a head-to-head study comparing the safety and efficacy of TYSABRI to Rebif *. Do notRS , is a randomized, evaluator-blinded, parallel group study that is more than 1,000 multiple sclerosis patients participating in the Americas, Australia, Turkey and Israel.In these patients, Session on Management options in metastatic prostate cancer a .

UroToday.com – One poster session of on ‘management options available in metastatic prostate cancer 1’found in EAU on the Wednesday 21 March 2007. Two placards of this session will be covered here.

Other Posts From "revitalization":

Related Posts